SYRE · Spyre Therapeutics, Inc.
$97.89
-2.08 (-2.08%)
At close · Jul 29
Going-concern doubt
— flagged May 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed May 5, 2026
Market Cap
$8.68B
Shares
86.84M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Cameron Turtle | CEO | $6,707,361 |
| Sheldon Sloan | Chief Medical Officer | $2,211,805 |
| Scott Burrows | CFO | $2,192,045 |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary | $2,192,045 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Sheldon Sloan | Chief Medical Officer | $9,388,740 |
| Cameron Turtle | CEO | $6,960,186 |
| Scott Burrows | CFO | $2,207,366 |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary | $2,051,909 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Cameron Turtle | CEO | $15,919,545 |
| Jonathan Alspaugh | CFO | $8,360,029 |
| Scott Burrows | CFO | $7,551,539 |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary | $6,588,281 |
| Jeffrey M. Goldberg | CEO | $830,207 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Anthony G. Quinn | CEO | $2,392,254 |
| Jeffrey M. Goldberg | CEO | $1,832,485 |
| Leslie Sloan | COO | $1,087,882 |
| Jonathan Alspaugh | CFO | $1,011,840 |
| Jim Kastenmayer | General Counsel and Corporate Secretary | $865,785 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Anthony G. Quinn | CEO | $2,623,186 |
| Leslie Sloan | COO | $1,449,436 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Harwin | the Board | Resigned | 2026-05-29 |
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
22 filings
22 filers
Visit website
Investor relations